Objective: To improve quality-of-life and health care delivery to patients receiving ureteral stents.
Specific Aims: Evaluate the feasibility, practicality, and qualitative outcomes of utilizing intra-nasal ketorolac in patients with indwelling ureteral stents (Phase I), followed by a randomized trial comparing two non-steroidal anti-inflammatory drugs, intra-nasal Ketorolac versus oral Diclofenac.
Hypotheses: Due to its favorable pharmacokinetics in relieving acute pain, investigators expect improved pain scores and a lower rate of unplanned clinical encounters in patients receiving intra-nasal ketorolac compared to those taking oral diclofenac following ureteroscopic surgery for urolithiasis.
Study Rationale: Following ureteroscopic management of urolithiasis, patient with indwelling ureter stents have higher levels of discomfort compared to those without a ureter stent. Prior studies showed that intramuscular Ketorolac at time of ureter stent removal decreased the incidence of unplanned clinical encounters. Furthermore, onset of analgesic effect by intra-nasal ketorolac is faster than its oral form, and similar its intramuscular and intravenous counterparts.

开始日期2024-05-01

申办/合作机构

The University of Texas Southwestern Medical Center

[+1]

NCT06326983 / Not yet recruitingN/AIIT

Opioid Sparing Anesthesia Care for Pediatric Patients Having Tonsil Surgery; a Randomized, Controlled, Non-inferiority Study

This is a prospective, randomized, controlled, non-inferiority study of patients undergoing tonsil surgeries at Boston Children's Hospital Waltham. The overall aim is to evaluate the efficacy of an opioid anesthetic plan (morphine, ketorolac, and acetaminophen versus an opioid sparing anesthetic plan (dexmedetomidine, ketorolac and acetaminophen) for perioperative analgesia and recovery time in patients undergoing tonsillectomies and tonsillotomies at Boston Children's Hospital Waltham. Secondary measures include rescue opioids administered in post-anesthesia care unit (PACU), re-operation secondary to bleeding, emergence delirium, post-operative nausea and vomiting, intraoperative hemodynamics, intraoperative vasopressor administration, and length of procedure.

开始日期2024-04-01

申办/合作机构

The Children's Hospital Corp.

NCT06081101 / Not yet recruiting早期临床1期IIT

Ultrasound Guided Sacroiliac Joint Injections With Ketorolac Versus Corticosteroid: A Prospective Non-inferiority Study

This study will contribute to the current literature that have compared joint injections with steroid versus ketorolac providing evidence for the use of ketorolac for SI joint pain. Currently steroid is the clinical standard for joint injections, however with repetitive use, steroid injections can damage the joint. Ketorolac is an alternative anti-inflammatory medication that does not cause the same joint damage and at a cheaper cost than steroid. The investigators hypothesize that ultrasound guided SI joint injections utilizing ketorolac provide the same pain relief as corticosteroid SI joint injections measured at 2, 6 and 12 weeks post injection. This would allow more frequent injections to control pain at a decreased cost to the healthcare system.

开始日期2024-04-01

申办/合作机构

McMaster University

100 项与酮咯酸相关的临床结果

登录后查看更多信息

100 项与酮咯酸相关的转化医学

登录后查看更多信息

100 项与酮咯酸相关的专利（医药）

登录后查看更多信息

3,247

项与酮咯酸相关的文献（医药）

2024-05-07·Regional anesthesia and pain medicine

Single-bolus injection of local anesthetic, with or without continuous infusion, for interscalene brachial plexus block in the setting of multimodal analgesia: a randomized controlled unblinded trial.

Article

作者: Rossel, Jean-Benoit ; Cachemaille, Matthieu ; Farron, Alain ; Goetti, Patrick ; Rhyner, Patrick ; Boand, Melanie ; Albrecht, Eric

INTRODUCTIONPrevious trials favored a continuous interscalene brachial plexus block over a single injection for major shoulder surgery. However, these trials did not administer a multimodal analgesic regimen. This randomized, controlled unblinded trial tested the hypothesis that a continuous infusion of local anesthetic for an interscalene brachial plexus block still provides superior analgesia after major shoulder surgery when compared with a single injection in the setting of multimodal analgesia, inclusive of intravenous dexamethasone, magnesium, acetaminophen and ketorolac.METHODSSixty patients undergoing shoulder arthroplasty or arthroscopic rotator cuff repair were randomized to receive a bolus of ropivacaine 0.5%, 20 mL, with or without a continuous infusion of ropivacaine 0.2% 4-8 mL/hour, for an interscalene brachial plexus block. Patients were provided with intravenous morphine patient-controlled analgesia. The primary outcome was cumulative intravenous morphine consumption at 24 hours postoperatively. Secondary outcomes included pain scores at rest and on movement, and functional outcomes, measured over 48 hours after surgery.RESULTSMedian (IQR) cumulative intravenous morphine consumption at 24 hours postoperatively was 10 mg (4-24) in the continuous infusion group and 14 mg (8-26) in the single injection group (p=0.74). No significant between-group differences were found for any of the secondary outcomes.CONCLUSIONSA continuous infusion of local anesthetic for an interscalene brachial plexus block does not provide superior analgesia after major shoulder surgery when compared with a single injection in the setting of multimodal analgesia, inclusive of intravenous dexamethasone, magnesium, acetaminophen and ketorolac. The findings of this study are limited by performance and detection biases.TRIAL REGISTRATION NUMBERNCT04394130.

2024-05-01·Veterinary Anaesthesia and Analgesia

A comparative analysis of opioid-free and opioid-sparing anaesthesia techniques for laparoscopic ovariectomy in healthy dogs

Article

作者: Gioeni, Daniela ; Del Prete, Giulia ; Sala, Giulia ; Carotenuto, Alessandra M ; Lazzarini, Eleonora ; Baio, Matteo

OBJECTIVETo compare the perioperative analgesic effects of an opioid-free (OFA) and an opioid-sparing (OSA) anaesthetic protocol in dogs undergoing laparoscopic ovariectomy.STUDY DESIGNProspective, randomized, blinded, clinical trial.ANIMALSA group of 28 client-owned dogs.METHODSDogs were allocated to one of two groups. The OFA group was administered intramuscular (IM) dexmedetomidine 5 μg kg^-1 and ketamine 1 mg kg^-1, followed by two intraoperative constant rate infusions (CRIs) of dexmedetomidine (3 μg kg^-1 hour^-1) and lidocaine (1 mg kg^-1 loading dose, 2 mg kg^-1 hour^-1). The OSA group was administered IM dexmedetomidine 5 μg kg^-1, ketamine 1 mg kg^-1 and methadone 0.2 mg kg^-1, followed by two intraoperative saline CRIs. In both groups, anaesthesia was induced with intravenous (IV) propofol 2 mg kg^-1 and diazepam 0.2 mg kg^-1 and maintained with isoflurane. Rescue dexmedetomidine (0.5 μg kg^-1) was administered IV if there was a 20% increase in cardiovascular variables compared with pre-stimulation values. Ketorolac (0.5 mg kg^-1) was administered IV when the surgery ended. Postoperative analgesia was evaluated using the Short Form-Glasgow Composite Measure Pain Scale and methadone (0.2 mg kg^-1) was administered IM if the pain score was ≥ 6/24. Statistical analysis included mixed analysis of variance, Chi-square test and Mann-Whitney U test.RESULTSThere were no significant differences in the intraoperative monitored variables between groups. The OFA group showed a significantly lower intraoperative rescue analgesia requirement (p = 0.016) and lower postoperative pain scores at 3 (p =0.001) and 6 (p < 0.001) hours. No dogs were administered rescue methadone postoperatively.CONCLUSIONS AND CLINICAL RELEVANCEAlthough both groups achieved acceptable postoperative pain scores with no need for further intervention, the analgesic efficacy of the OFA protocol was significantly superior to that of the OSA protocol presented and was associated with a lower intraoperative rescue analgesia requirement and early postoperative pain scores.

2024-05-01·Biomaterials Advances

Development of novel hybrid 3D-printed degradable artificial joints incorporating electrospun pharmaceutical- and growth factor-loaded nanofibers for small joint reconstruction

Article

作者: Hsu, Yung-Heng ; Liu, Shih-Jung ; Lu, Chia-Jung ; Chen, Chao-Lin ; Chou, Ying-Chao ; Yu, Yi-Hsun

Small joint reconstruction remains challenging and can lead to prosthesis-related complications, mainly due to the suboptimal performance of the silicone materials used and adverse host reactions. In this study, we developed hybrid artificial joints using three-dimensional printing (3D printing) for polycaprolactone (PCL) and incorporated electrospun nanofibers loaded with drugs and biomolecules for small joint reconstruction. We evaluated the mechanical properties of the degradable joints and the drug discharge patterns of the nanofibers. Empirical data revealed that the 3D-printed PCL joints exhibited good mechanical and fatigue properties. The drug-eluting nanofibers sustainedly released teicoplanin, ceftazidime, and ketorolac in vitro for over 30, 19, and 30 days, respectively. Furthermore, the nanofibers released high levels of bone morphogenetic protein-2 and connective tissue growth factors for over 30 days. An in vivo animal test demonstrated that nanofiber-loaded joints released high concentrations of antibiotics and analgesics in a rabbit model for 28 days. The animals in the drug-loaded degradable joint group showed greater activity counts than those in the surgery-only group. The experimental data suggest that degradable joints with sustained release of drugs and biomolecules may be utilized in small joint arthroplasty.

项与酮咯酸相关的新闻（医药）

2024-02-26

·信狐药迅

兆科痤疮新药阿达帕林克林霉素凝胶，卓和中药新药风叶咳喘平口服液获批文 | 新获批（2.19-2.25）

每周药品注册受理数据，分门别类呈现，一目了然。（2.19-2.25）新药上市申请药品名称企业名称分类受理号阿达帕林盐酸克林霉素复方凝胶兆科(广州)眼科药物有限公司2.3CXHS2100002特立帕肽注射液上海联合赛尔生物工程有限公司3.3CXSS2200068新药临床申请药品名称企业名称分类受理号ADC189颗粒嘉兴安谛康生物科技有限公司1CXHL2301377BEBT-109胶囊广州必贝特医药股份有限公司1CXHL2301363BEBT-109胶囊广州必贝特医药股份有限公司1CXHL2301364GLB-001胶囊杭州格博生物医药有限公司1CXHL2301360GLB-001胶囊杭州格博生物医药有限公司1CXHL2301361GLB-001胶囊杭州格博生物医药有限公司1CXHL2301362HP537片海创药业股份有限公司1CXHL2301351HP537片海创药业股份有限公司1CXHL2301352HRS-1167片江苏恒瑞医药股份有限公司1CXHL2301200JMKX003561颗粒浙江杭煜制药有限公司1CXHL2301356JMKX003561颗粒浙江杭煜制药有限公司1CXHL2301357JP-1366片丽珠集团丽珠医药研究所1CXHL2301335JW202232吸入气雾剂山东泰合医药科技有限公司2.2CXHL2301319TL938胶囊苏州韬略生物科技股份有限公司1CXHL2301355盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2301373盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2301374盐酸安罗替尼胶囊正大天晴药业集团股份有限公司2.4CXHL2301375aT19注射液北京永泰瑞科生物科技有限公司1CXSL2300808JWK001注射液成都金唯科生物科技有限公司1CXSL2300827QX007N注射液江苏荃信生物医药股份有限公司1CXSL2300850WG1025北京唯源立康生物科技股份有限公司1CXSL2300809注射用HS-20089上海翰森生物医药科技有限公司1CXSL2300849注射用PRO1107普方生物制药(苏州)有限公司1CXSL2300847注射用SIBP-A17上海生物制品研究所有限责任公司1CXSL2300851重组带状疱疹疫苗(CHO细胞)上海生物制品研究所有限责任公司1.3CXSL2300817重组带状疱疹疫苗(CHO细胞)上海生物制品研究所有限责任公司1.3CXSL2300818仿制药申请药品名称企业名称分类受理号丙泊酚中/长链脂肪乳注射液石家庄四药有限公司4CYHS2201195丙泊酚中/长链脂肪乳注射液石家庄四药有限公司4CYHS2201196乙酰半胱氨酸泡腾片宁波美诺华天康药业有限公司4CYHS2201771乙酰半胱氨酸泡腾片江苏安必生制药有限公司4CYHS2201683低钙腹膜透析液(乳酸盐-G1.5)上海华源安徽锦辉制药有限公司4CYHS2201024低钙腹膜透析液(乳酸盐-G2.5)上海华源安徽锦辉制药有限公司4CYHS2201009依托考昔片山西同达药业有限公司4CYHS2200527依托考昔片山西同达药业有限公司4CYHS2200528依替巴肽注射液沈阳双鼎制药有限公司3CYHS2200579利伐沙班片天津力生制药股份有限公司4CYHS2201017利伐沙班片天津力生制药股份有限公司4CYHS2201018利伐沙班片天津力生制药股份有限公司4CYHS2201016利奈唑胺葡萄糖注射液江苏晨牌药业集团股份有限公司4CYHS2200161去氧肾上腺素酮咯酸溶液苏州朗易生物医药研究有限公司3CYHS2301443吡拉西坦注射液华夏生生药业(北京)有限公司3CYHS2201887吡拉西坦注射液华夏生生药业(北京)有限公司3CYHS2201888吲哚布芬片仁合益康集团有限公司3CYHS2301213吸入用乙酰半胱氨酸溶液云南龙海天然植物药业有限公司4CYHS2201984呋塞米口服液成都倍特得诺药业有限公司3CYHS2200938地夸磷索钠滴眼液成都普什制药有限公司4CYHS2201668地屈孕酮片杭州和泽坤元药业有限公司4CYHS2201435头孢地尼颗粒海南葫芦娃药业集团股份有限公司4CYHS2200370头孢托仑匹酯颗粒北京诚济制药股份有限公司4CYHS2302749奥硝唑注射液西安信百欣医药科技有限公司3CYHS2201249奥硝唑注射液西安信百欣医药科技有限公司3CYHS2201250对乙酰氨基酚维生素C泡腾片山东新鲁医药科技有限公司3CYHS2301569左乙拉西坦缓释片华润赛科药业有限责任公司3CYHS2200992左乙拉西坦缓释片华润赛科药业有限责任公司3CYHS2200993己酮可可碱注射液山东泰合医药科技有限公司3CYHS2201467异硫蓝注射液广东和博制药有限公司3CYHS2200409枸橼酸托法替布片黑龙江珍宝岛药业股份有限公司4CYHS2102173氟维司群注射液轩竹生物科技股份有限公司4CYHS2201150氢溴酸伏硫西汀片辰欣药业股份有限公司4CYHS2201399氢溴酸伏硫西汀片辰欣药业股份有限公司4CYHS2201400氧湖南昇宇科技开发有限公司4CYHS2300752氨磺必利口服溶液山东朗诺制药有限公司3CYHS2201774氯化钾注射液广州艾奇西医药科技有限公司3CYHS2201393氯化钾注射液广州艾奇西医药科技有限公司3CYHS2201394氯化钾注射液海南紫程众投生物科技有限公司3CYHS2201317氯化钾颗粒杭州和泽坤元药业有限公司3CYHS2201694氯替泼诺妥布霉素滴眼液天津金耀药业有限公司4CYHS2300842氯雷他定糖浆河北三禾实创生物科技有限公司4CYHS2300789氯雷他定糖浆河北三禾实创生物科技有限公司4CYHS2300790注射用头孢他啶阿维巴坦钠上海欣峰制药有限公司4CYHS2200952注射用盐酸瑞芬太尼宜昌人福药业有限责任公司3CYHS2202145注射用盐酸瑞芬太尼宜昌人福药业有限责任公司3CYHS2202146注射用盐酸瑞芬太尼宜昌人福药业有限责任公司3CYHS2202147注射用盐酸罗沙替丁醋酸酯北京品尚品医药科技有限公司3CYHS2200371注射用艾司奥美拉唑钠重庆中创科医药有限公司4CYHS2201720注射用阿扎胞苷齐鲁制药(海南)有限公司4CYHS2200759盐酸帕罗西汀片江苏睿实生物科技有限公司4CYHS2201063盐酸氨溴索口服溶液南京卡文迪许生物工程技术有限公司4CYHS2300569盐酸特比萘芬喷雾剂华润三九医药股份有限公司4CYHS2200820盐酸特比萘芬喷雾剂浙江恒研医药科技有限公司4CYHS2200544盐酸纳洛酮注射液东阳祥昇医药科技有限公司3CYHS2201420盐酸达泊西汀片江苏万高药业股份有限公司4CYHS2201054盐酸鲁拉西酮片辰欣药业股份有限公司4CYHS2102298硝酸甘油葡萄糖注射液仁合益康集团有限公司3CYHS2301226硝酸甘油葡萄糖注射液仁合益康集团有限公司3CYHS2301227硫酸氨基葡萄糖胶囊青岛百洋制药有限公司4CYHS2201008硫酸特布他林注射液成都利尔药业有限公司3CYHS2200341硫酸镁注射液北京民康百草医药科技有限公司3CYHS2201519碳酸氢钠林格注射液石家庄四药有限公司3CYHS2201309磷酸奥司他韦胶囊吉林敖东洮南药业股份有限公司4CYHS2201343磷酸奥司他韦胶囊吉林敖东洮南药业股份有限公司4CYHS2201344磷酸奥司他韦胶囊吉林敖东洮南药业股份有限公司4CYHS2201345维格列汀片惠升生物制药股份有限公司4CYHS2201303罗库溴铵注射液吉林振澳制药有限公司4CYHS2200841罗库溴铵注射液吉林振澳制药有限公司4CYHS2200842美阿沙坦钾片仁合益康集团有限公司4CYHS2301049美阿沙坦钾片仁合益康集团有限公司4CYHS2301050聚乙烯醇滴眼液远大医药(中国)有限公司3CYHS2300885舒更葡糖钠注射液海南睿智医药科技投资有限公司4CYHS2200321西格列汀二甲双胍缓释片上海安必生制药技术有限公司3CYHS2200155西洛他唑片北京福元医药股份有限公司3CYHS2201576酒石酸溴莫尼定滴眼液北京诺思兰德生物技术股份有限公司4CYHS2200665酮咯酸氨丁三醇注射液江苏明圣康源药业有限公司3CYHS2303616酮咯酸氨丁三醇注射液成都瑞尔医药科技有限公司3CYHS2300791铝碳酸镁混悬液四川益生智同医药生物科技发展有限公司3CYHS2200912长链脂肪乳注射液(OO)成都国为生物医药有限公司4CYHS2200467阿司匹林肠溶片江苏万高药业股份有限公司4CYHS2201656阿哌沙班片华润双鹤药业股份有限公司4CYHS2201597阿立哌唑口服溶液山东百诺医药股份有限公司3CYHS2201251骨化三醇软胶囊江苏中治制药有限公司4CYHS2201535进口申请药品名称企业名称分类受理号Camonsertib胶囊F.Hoffmann-La Roche Ltd.1JXHL2300307CagriSema注射液Novo Nordisk A/S1JXSL2300221CagriSema注射液Novo Nordisk A/S1JXSL2300222CagriSema注射液Novo Nordisk A/S1JXSL2300223CagriSema注射液Novo Nordisk A/S1JXSL2300224CagriSema注射液Novo Nordisk A/S1JXSL2300225MK-7240注射液Merck Sharp & Dohme LLC1JXSL2300219MK-7240注射用浓溶液Merck Sharp & Dohme LLC1JXSL2300220SAR443765注射液Sanofi-Aventis Recherche & Developpement1JXSL2300216注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300208注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300209注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300210注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300211注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300212注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300213注射用重组单链人凝血因子VIIICSL Behring GmbH3.1JXSL2300214恩曲替尼胶囊Roche Pharma (Schweiz) AG5.1JXHS2300045恩曲替尼胶囊Roche Pharma (Schweiz) AG5.1JXHS2300046硫酸羟氯喹片Amneal EU, Limited5.2JYHS2300128醋酸锌片Nobelpharma Co.,Ltd.5.1JXHS2300017醋酸锌片Nobelpharma Co.,Ltd.5.1JXHS2300018珂罗利单抗注射液Roche Pharma (Schweiz) AG1JXSS2200031中药相关申请药品名称企业名称分类受理号风叶咳喘平口服液卓和药业集团股份有限公司1.1CXZS2200014注：灰色字体部分结论为不批准或收到通知件；

申请上市抗体药物偶联物疫苗

2024-02-23

·生物探索

Circulation | 南京医科大学季勇/谢利平/王东进发现加重主动脉瘤和夹层的新机理

引言S-亚硝基化(SNO)是一种典型的基于氧化还原的翻译后修饰，与心血管疾病有关。主动脉瘤和夹层是目前尚无有效治疗方法的高危心血管疾病。2024年2月15日，南京医科大学季勇、谢利平及王东进共同通讯在Circulation (IF 38)在线发表题为“S-Nitrosylation of Septin2 Exacerbates Aortic Aneurysm and Dissection by Coupling the TIAM1-RAC1 Axis in Macrophages”的研究论文，该研究表明巨噬细胞中Septin2的S-亚硝基化通过偶联TIAM1-RAC1轴加重主动脉瘤和夹层。在接受主动脉夹层手术的患者和注射血管紧张素II的Apoe-/-小鼠的主动脉组织中，Septin2被鉴定为S-亚硝基化的半胱氨酸111 (Cys111)。SNO-Septin2被证实可促进主动脉瘤和夹层的发展。通过RNA测序，证实巨噬细胞中的SNO-Septin2可加剧主动脉瘤血管炎症和细胞外基质降解。接下来，TIAM1 (T淋巴瘤侵袭和转移诱导蛋白1)被确定为SNO-Septin2的靶蛋白。机制上，与未修饰的Septin2相比，SNO-Septin2减少了与TIAM1的相互作用，激活了TIAM1- RAC1轴及其相关的核因子-κB信号通路，导致巨噬细胞介导的炎症和细胞外基质降解更强。一致地，R-Ketorolac和NSC23766治疗通过抑制TIAM1-RAC1轴来保护主动脉瘤和夹层。总之，SNO-Septin2通过偶联巨噬细胞中的TIAM1-RAC1轴，激活核因子-κB信号通路依赖性炎症和细胞外基质降解，驱动主动脉瘤和夹层。因此，R-Ketorolac或NSC23766对RAC1的药理学阻断可能是治疗主动脉瘤和夹层的潜在方法。主动脉瘤和主动脉夹层是高死亡率的心血管疾病。主动脉瘤的特征是主动脉局部或弥漫性扩张，这逐渐增加了急性主动脉夹层的风险。主动脉夹层被定义为内膜破裂，导致主动脉壁层分离，随后形成真腔和假腔。尽管在影像学和血管开放修复和血管内修复方面取得了重大进展，但有效的药物治疗仍然不可用。巨噬细胞积聚在动脉瘤主壁上，通过影响细胞外基质(ECM)降解和炎症，促进了动脉瘤和夹层的发生研究发现，浸润于主动脉瘤血管壁及夹层的大量巨噬细胞高度表达诱导型一氧化氮(NO)合成酶(iNOS)，可催化产生大量NO，并通过蛋白S-亚硝基化(SNO)发挥多种病理生理作用。SNO是将NO部分可逆的共价加成到半胱氨酸硫醇上，形成S-亚硝基蛋白，参与心脏肥厚、心脏纤维化、动脉粥样硬化等多种心血管疾病的发病。因此，SNO可能发生在主动脉瘤及夹层血管组织中iNOS高表达并参与主动脉瘤及夹层的巨噬细胞中。Cys111突变的Septin2减轻主动脉瘤（Credit: Circulation）Septin2属于Septin家族。Septin是一个高度保守的蛋白家族，在细胞分裂、细胞内物质运输、细胞周期调节和细胞凋亡中被越来越多地认为是细胞骨架的一个新组成部分。已被证明在阿尔茨海默病、癌症、感染和系统性红斑狼疮中发挥重要作用Septin2参与维持内皮细胞连接和内皮完整性。Septin2还可以通过增强内皮细胞的迁移来促进血管生成。然而，Septin2在主动脉瘤和夹层中的作用尚不清楚。该研究证实了在半胱氨酸111 (Cys111)位点Septin2的SNO加重血管紧张素II (Ang II)诱导的主动脉瘤和β-氨基丙腈(BAPN)诱导的主动脉瘤和夹层。机制上，SNO-Septin2减少其与巨噬细胞中TIAM1 (T淋巴瘤侵袭和转移诱导蛋白1)的相互作用，激活TIAM1RAC1 (Ras相关的C3肉毒毒素底物1)轴及其相关的核因子-κB (NF-κB)信号通路，促进更强的炎症反应和ECM降解。总之，这些发现表明SNO-Septin2可能是动脉瘤和夹层的治疗靶点。原文链接https://doi-org.libproxy1.nus.edu.sg/10.1161/CIRCULATIONAHA.123.066404责编|探索君排版|探索君文章来源|“iNature”End往期精选围观一文读透细胞死亡(Cell Death) | 24年Cell重磅综述（长文收藏版）热文Nature | 破除传统：为何我们需要重新思考肿瘤的命名方式热文Nature | 2024年值得关注的七项技术热文Nature | 自身免疫性疾病能被治愈吗？科学家们终于看到了希望热文Nature | 癌症与神经系统的致命舞蹈

2024-02-13

·BioSpace

Yinuoke publication demonstrates a new orally delivered molecule that reverses cancer cachexia and increases survival using in vivo models

Yinuoke, a biopharmaceutical company pioneering breakthrough therapeutics for late-stage cancer patients announced today the publication of a manuscript in the peer-reviewed Journal of Cachexia, Sarcopenia and Muscle demonstrating the effectiveness of a new compound in alleviating cachexia and increasing the survival of tumor-bearing mice in a T-cell dependent manner. Cancer cachexia, a devastating tumor-induced immune disorder leading to body wasting and reduced tolerability to therapeutics, occurs in 80% of all cancer patients and causes 25% of deaths. Previous attempts to treat cachexia have failed due to lack of efficacy in stabilizing patient weight and strength. Yinuoke treats cachexia as a tumor-driven autoimmune disorder rather than a metabolic condition. YNK105 reduces systemic inflammation without the toxic side effects caused by NSAIDS that limit its use. The data shows a significant improvement in cachexigenic tumor-bearing mice in overall survival, increases in body, fat, and muscle weight, and reductions in plasma IL-6 and tissue- derived Stat3. Most impressively, cachectic mice achieved a 100% survival rate with a combination treatment of YNK105 and chemotherapy. “This research is the first demonstration that severe cachexia can be halted and reversed”, said Dr. Lingbing Zhang, founder and CEO of Yinuoke. “The ability to reverse cachexia expands the options for late-stage cancer patients to extend survival and live a higher quality of life. Reversing cachexia requires modulating the immune system’s inflammatory response for longer than an NSAID will allow. We identified R-ketorolac as a potential treatment for cachexia and now have significant evidence to support a superior efficacy and safety pro to current approaches using GDF-15 inhibitors or Anamorelin.” “YNK105 has the potential to be a breakthrough treatment for cancer cachexia that I am excited to bring into the clinic,” said Dr. Andrew Hendifar of Cedars-Sinai. “Pancreatic cancer patients are highly susceptible to cachexia and treatment outcomes are severely impacted. Getting control of cachexia is critical for overall survival of patients with pancreatic cancer and especially for stage 4 and late diagnosed patients. These early studies support moving this program into clinical trials.” The research appearing in the February 1st issue of the Journal of Cachexia, Sarcopenia and Muscle is led by Dr. Martina Schweiger and a team of scientists at the Institute of Molecular Biosciences, University of Graz, Austria. About Yinuoke Yinuoke is on a mission to save lives and conquer late-stage cancer through groundbreaking science and the development of first-in-class therapies where no options currently exist. Our vision is to revolutionize late-stage cancer by pushing boundaries and transforming it from a terminal disease to a manageable lifelong condition. Through innovative approaches and tailored treatments, we aim to empower patients with new possibilities for long-term remission and improved quality of life. For inquiries on partnering and investing please contact Suzanne Kennedy at skennedy@yinuokeus.com.

临床结果

100 项与酮咯酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08104	酮咯酸	-	DB00465

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨关节炎	临床3期	美国	Mayo Clinic	2023-07-28
术后疼痛	临床3期	-	Neumentum, Inc.初创企业	-
术后炎症	临床1期	美国	Layerbio, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed	N/A	-	18	S (-) ketorolac	(鹹廠淵廠構遞壓鑰艱廠) = 蓋鏇齋窪糧蓋鏇簾餘觸觸獵糧憲觸選壓願選觸 (憲網製築獵築膚壓範遞 ) 更多	-	2019-09-01
				R (+) ketorolac	(鹹廠淵廠構遞壓鑰艱廠) = 醖鏇醖衊繭觸蓋鹽糧網觸獵糧憲觸選壓願選觸 (憲網製築獵築膚壓範遞 ) 更多
AAO2022	N/A	眼科外科手术	-	Epinephrine alone	(鏇鏇糧繭衊構襯蓋簾製) = 憲顧窪製糧憲繭膚鏇鏇願膚積淵願齋繭選襯壓 (襯壓構蓋廠繭積餘膚壓 ) 更多	-	2022-09-29
				Omidria (intracameral phenylephrine and ketorolac)	(鏇鏇糧繭衊構襯蓋簾製) = 蓋構夢壓餘構鏇齋淵積願膚積淵願齋繭選襯壓 (襯壓構蓋廠繭積餘膚壓 ) 更多
PO323 (AAO2019)	N/A	眼科外科手术	-	Intravenous Ketorolac (IVK)	(醖鹽遞蓋鹹鹽鹹夢鏇築) = 構夢廠積顧膚餘鑰襯齋選壓膚範構構糧鑰壓壓 (築壓築網衊醖醖鬱鏇艱 )	积极	2019-10-12
				Ketorolac	(醖鹽遞蓋鹹鹽鹹夢鏇築) = 顧襯網鹽艱鏇築構鬱襯選壓膚範構構糧鑰壓壓 (築壓築網衊醖醖鬱鏇艱 )
2019 ARVO Annual Meeting (ARVO2019)	N/A	瞳孔散大	214	2.5% phenylephrine, 0.5% tropicamide, and 0.5% ketorolac	(壓簾廠選獵觸廠襯範鏇) = 鑰糧窪網齋蓋膚夢衊範簾膚夢範構構選壓齋鹹 (構糧襯範齋膚鹹築選繭 )	-	2019-07-01
				10% phenylephrine, 0.5% tropicamide, and 0.5% ketorolac	(壓簾廠選獵觸廠襯範鏇) = 鑰廠襯夢膚衊選糧鹹鑰簾膚夢範構構選壓齋鹹 (構糧襯範齋膚鹹築選繭 )
ADA2019	N/A	-	-	Lispro	積築艱繭構網構繭製鬱(範構築淵窪範鏇築淵糧) = 淵鑰淵壓觸廠觸膚獵餘鹹糧窪膚鏇製獵築網餘 (憲襯範觸糧鬱繭觸繭範 ) 更多	-	2019-06-01
				Mixed solution (lispro + ketorolac)	積築艱繭構網構繭製鬱(範構築淵窪範鏇築淵糧) = 壓繭襯夢繭鹽選憲獵鹹鹹糧窪膚鏇製獵築網餘 (憲襯範觸糧鬱繭觸繭範 ) 更多
NCT02132312 (Pubmed \| J Cataract Refract Surg) 人工标引	临床3期	疼痛	72	phenylephrine +ketorolac	(憲膚蓋構顧艱選鏇壓鏇) = There were no notable changes in vital signs or ophthalmological complications in either group. 構簾醖簾窪簾選壓廠淵 (廠繭積網壓繭願築襯夢 ) 更多	积极	2020-06-01
				phenylephrine (PE) 1.0%
TCTR20200909006 (Pubmed) 人工标引	临床3期	德凯尔费恩病	60	Lidocaine+Adrenaline+Ketorolac	襯築淵繭願繭鹹觸積襯(夢鑰鑰膚築鏇構觸廠製) = 鹹簾醖鬱範壓鹽製糧範衊餘獵鹹淵醖網顧廠顧 (鏇構淵網憲窪觸鹽餘艱, 2.0)	不佳	2022-09-01
				Lidocaine+Adrenaline+Triamcinolone Acetonide	襯築淵繭願繭鹹觸積襯(夢鑰鑰膚築鏇構觸廠製) = 夢襯鏇築齋製壓網簾壓衊餘獵鹹淵醖網顧廠顧 (鏇構淵網憲窪觸鹽餘艱, 3.2)
ESMO_ASIA_VIRTUAL2020	N/A	疼痛 \| 盆腔肿瘤	-	Epidural catheter placement with bupivacaine and morphine	(製鹽齋遞鑰築醖範遞鏇) = Constipation was not admitted in the main group. In 3-months observation period, 11 (32.6) patients from second group had complains on constipation which was resolved with laxatives and enemas. 糧襯憲鑰築製醖壓鹽鹹 (鹹製糧鏇廠繭醖網鑰壓 ) 更多	积极	2020-11-22
				Standard WHO pain ladder therapy with morphine and ketorolac
PD26-02 (AUA2021)	N/A	-	-	Ketorolac	襯選顧襯廠鬱衊築網蓋(襯鹽顧築蓋醖廠襯積鬱) = 構構壓窪餘簾鬱齋襯簾獵餘範廠淵廠繭觸鹹壓 (積蓋鏇憲鏇齋廠醖鬱廠 ) 更多	积极	2021-09-01
				TORADOL (KETOROLAC) (Control)	襯選顧襯廠鬱衊築網蓋(襯鹽顧築蓋醖廠襯積鬱) = 築廠糧築積網選鏇觸艱獵餘範廠淵廠繭觸鹹壓 (積蓋鏇憲鏇齋廠醖鬱廠 ) 更多
2020 ARVO Annual Meeting (ARVO2020)	N/A	术后炎症	470	Combination of topical prednisolone and ketorolac (NSAID)	(願範獵願壓鹽遞夢餘蓋) = 襯鹽網選憲積壓積餘衊獵廠築壓鹽淵選範築壓 (鑰醖襯網壓網築構獵糧, 47.4% ~ 89.2%) 更多	不佳	2020-06-01
				Ketorolac alone	(願範獵願壓鹽遞夢餘蓋) = 獵窪糧選壓遞鏇鬱蓋範獵廠築壓鹽淵選範築壓 (鑰醖襯網壓網築構獵糧, 59.4% ~ 103.8%) 更多